N/A
Completed N=60
De-implementation of Low Value Castration for Men With Prostate Cancer
Cancer of Prostate
Source: ClinicalTrials.gov NCT03579680 ↗
Enrolled (actual)
60
Serious AEs
—
Results posted
Sep 2024
Primary outcomePrimary: Feasibility - Site Level: Medical Center Director (MCD) Approval — 3; 1 sites
Summary
This study will use a theory-based, mixed methods approach to identify, tailor and pilot two different de-implementation strategies that vary widely in delivery, impact, and expected results for reducing low value androgen deprivation therapy (ADT) use in preparation for a randomized comparative effectiveness trial comparing two tailored deimplementation strategies to reduce chemical castration as localized prostate cancer treatment and treatment for non-metastatic biochemical recurrence with low PSA levels.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility - Site Level: Medical Center Director (MCD) Approval |
3; 1 | — |
| PRIMARY Feasibility - Site Level: Fully Operationalized Intervention |
2; 1 | — |
| PRIMARY Feasibility - Clinic Level: Clinics With Intervention Implementation |
2; 1 | — |
| SECONDARY Reach |
46; 14 | — |
| SECONDARY Penetration - Provider Script (SC) |
5 | — |
| SECONDARY Penetration - OR |
8 | — |
Eligibility Criteria
Inclusion Criteria
- Any provider at participating sites who prescribes ADT for prostate cancer patients
Exclusion Criteria
- Providers opting out of study
Data sourced from ClinicalTrials.gov (NCT03579680). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.